{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"Any Grade increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"Increase to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Increase to Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"12"}],"units":"Participants"}],"description":"ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\\<450 milliseconds \\[msec\\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at the specified time point were analyzed.","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Number of Participants With Increase in QTcF-Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}